anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Chronic Myeloid Leukemia (CML) is a hematological malignancy characterized by the presence of the BCR::ABL1 fusion gene, which leads to uncontrolled cell growth and survival. Tyrosine kinase inhibitors (TKIs) have revolutionized the treatment of CML, but a significant proportion of patients develop resistance or lose response to these drugs. Understanding the molecular mechanisms underlying treatment response and resistance is crucial for improving patient outcomes. This study aimed to analyze the expression patterns of genes involved in treatment response and resistance in CML patients receiving TKI therapy. The expression levels of MET, FOXO3, p15, p16, HCK, and FYN genes were examined in CML patients and compared to healthy donors. Gene expression levels were compared between optimal responders (OR) and resistant patients (R) vs. healthy donors (HD). The MET and FOXO3 OR group showed significant differences compared with the HD, (p < 0.0001) and (p = 0.0003), respectively. p15 expression showed significant differences between OR and HD groups (p = 0.0078), while no significant differences were found in p16 expression between the HD groups. FYN showed a statistically significant difference between R vs. HD (p = 0.0157). The results of HCK expression analysis revealed significant differences between OR and HD (p = 0.0041) and between R and HD (p = 0.0026). When we analyzed OR patients with undetectable BCR::ABL1 transcripts, a greater expression of HCK was observed in the R group. These findings suggest that monitoring the expression levels of MET and FOXO3 genes could be valuable in predicting treatment response and relapse in CML patients. Our study provides important insights into the potential use of gene expression analysis as a tool for predicting treatment response and guiding treatment decisions in CML patients. This knowledge may ultimately contribute to the development of personalized treatment strategies to improve patient outcomes in CML.
Systems, methods, and instrumentalities are disclosed for switching a control scheme to control a set of system modules and/or modular devices of a surgical hub. A surgical hub may determine a first control scheme that is configured to control a set of system modules and/or modular devices. The surgical hub may receive an input from one of the set of modules or a device located in an OR. The surgical hub may make a determination that at least one of a safety status level or an overload status level of the surgical hub is higher than its threshold value. Based on at least the received input and the determination, the surgical hub may determine a second control scheme to be used to control the set of system modules. The surgical hub may send a control program indicating the second control scheme to one or more system modules and/or modular devices.
Participants who were administered 70 mg AMG 827 in parent study 20090061 and were administered 210 mg SC AMG 827 at Day 1, Week 1, Week 2 and Q2WK thereafter. Participants also continued to receive weekly intramuscular, oral or SC doses of methotrexate and folic acid or folate.
PROBLEM TO BE SOLVED: To obtain an antiseptic means being influenced by a nonionic surfactant in the presence of the nonionic surfactant. SOLUTION: In this cosmetic containing a nonionic surfactant, the cosmetic contains 1,2-pentanediol but not an antiseptic. An antiseptic is one or more selected from methylparaben, ethylparaben, propylparaben and phenoxyethanol. The cosmetic further contains a melanin production inhibitor which is selected from calcium pantethetine S sulfate, esculetin esculoside and magnesium ascorbate phosphate. The content of 1,2-dionediol is 0.1-10 wt.%. The cosmetic has pH 6-7 and is useful for sensitive skin.
The invention refers to genetic engineering, can be used in biotechnology, medicine, agriculture for creating gene therapy drugs. A gene therapy DNA vector based on gene therapy DNA vector VTvaflV carrying a therapeutic gene selected from the group of SOD1, SOD2, SOD3, CAT genes to increase the expression level of the therapeutic gene in humans and animals. The gene therapy DNA vector VTvaflV- SOD1 or VTvafl7-SOD2 or VTvafl7-SOD3 or VTvafl7-CAT has a nucleotide sequence SEQ ID No. 1 or SEQ ID No. 2 or SEQ ID No. 3 or SEQ ID No. 4, respectively. The vector does not contain nucleotide sequences of viral origin, antibiotic resistance genes, providing its safe use for genetic therapy in humans and animals. A method of production of the vector, a method of use of the vector, a  Escherichia coli  strain carrying the vector, a method of industrial production of the vector are proposed.
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Adverse Reactions in Adult Patients

The safety of XENOVIEW was evaluated in two prospective efficacy trials that enrolled a total of 83 adult patients with various lung disorders who were being evaluated for possible lung surgery [see Clinical Studies (14)]. Mean age of these patients was 62 years, 88% were White and 69% were male. In these two trials, mean xenon gas volume per XENOVIEW dose was 330.2 mL and 81 of 83 patients (98%) received a single administration of XENOVIEW. For safety assessment, the volume of administered xenon gas in the XENOVIEW dose is noted rather than the DE, because isotopic enrichment and hyperpolarization are not known to affect the safety profile of xenon gas.

Adverse reactions were reported in 12 (14%) of the 83 patients. Adverse reactions reported by more than one patient were oropharyngeal pain (n = 4 patients), headache (n = 2 patients), and dizziness (n = 2 patients).

A hypersensitivity reaction that included transient pruritus and erythema occurred in one patient with a history of allergic reactions to several drugs, foods, and other substances.

In pooled data of 123 adult patients from published literature, most of whom had lung disorders such as COPD, idiopathic pulmonary fibrosis, and asthma, who received 1 dose to 2 doses of hyperpolarized xenon Xe 129 with xenon volumes of approximately 500 mL to 1,000 mL of xenon gas per dose, the following transient adverse reactions were reported: numbness, tingling, euphoria, and dizziness. Overall frequency of these adverse reactions could not be determined from the published information.

Adverse Reactions in Pediatric Patients

In pooled data of 120 pediatric patients aged 6 to 18 years from published literature, most of whom had either asthma or cystic fibrosis, who received 1 dose to 2 doses of hyperpolarized xenon Xe 129 with xenon volumes based on predicted total lung capacity (TLC), the following transient adverse reactions were reported: blood oxygen desaturation, heart rate elevation, numbness, tingling, dizziness, and euphoria. Overall frequency of these adverse reactions could not be determined from the published information. XENOVIEW is not approved for use in pediatric patients less than 12 years of age.

In one of the published studies of 23 pediatric patients aged 6 to 18 years, 11 of whom had cystic fibrosis and 12 of whom were healthy, the mean difference of SpO2% from baseline was -6% following hyperpolarized xenon Xe 129 administration with xenon volumes based on predicted total lung capacity. In the same study, the mean change in heart rate from baseline was +6.6 beats per minute following hyperpolarized xenon Xe 129 administration. Both reported oxygen desaturation and heart rate elevation resolved by 2 minutes post-dose without intervention. XENOVIEW is not approved for use in pediatric patients less than 12 years of age.
PURPOSE: Extensor mechanism injuries, which comprise patella fractures, patella tendon tears and quadriceps tendon tears, are severely debilitating injuries and a common cause of traumatic knee pathology that requires surgical intervention. Risk factors for short-term surgical complications and venous thromboembolism (VTE) in this population have not been well characterised. The aim of this study was to identify perioperative risk factors associated with these short-term complications.
METHODS: The National Surgical Quality Improvement Program database was used to identify patients who underwent an isolated, primary extensor mechanism repair from 2015 to 2020. Patients were stratified by injury type. Demographic data were collected and compared. A multivariate logistic regression was used to control for demographic and comorbid factors while assessing risk factors for developing short-term complications.
RESULTS: A total of 8355 patients were identified for inclusion in this study. Overall, 3% of patients sustained short-term surgical complications and 1% were diagnosed with VTE within 30 days of surgery. Patella fracture fixation had a nearly twofold higher risk for surgical complications compared to quadriceps tendon repair (p = 0.004). Patella tendon repair had a twofold higher risk for VTE (p = 0.045), specifically deep vein thrombosis (p = 0.020), compared to patella fracture fixation. Increasing age, smoking and American Society of Anesthesiologists Classifications 3 and 4 were also found to be risk factors for surgical complications (p = 0.012, p = 0.004, p = 0.011 and p = 0.032, respectively).
CONCLUSION: This study used a nationally representative, widely validated, peer-reviewed database to provide valuable insights into risk factors for short-term postoperative complications associated with extensor mechanism repair procedures, revealing notable differences in risk profiles among distinct surgical procedures. The results of this study will inform surgeons and patients in enhancing risk assessment, guiding procedure-specific decision-making, optimising preoperative care, improving postoperative monitoring and contributing to future research of extensor mechanism injuries.
LEVEL OF EVIDENCE: Level III.
Hyperkalemia will rarely occur in patients with adequate urinary output, but it is a possibility if large doses are used for considerable periods of time. If hyperkalemia is observed, Triamterene should be withdrawn. The normal adult range of serum potassium is 3.5 to 5.0 mEq per liter, with 4.5 mEq often being used for a reference point. Potassium levels persistently above 6 mEq per liter require careful observation and treatment. Normal potassium levels tend to be higher in neonates (7.7 mEq per liter) than in adults. 

Serum potassium levels do not necessarily indicate true body potassium concentration. A rise in plasma pH may cause a decrease in plasma potassium concentration and an increase in the intracellular potassium concentration. Because triamterene conserves potassium, it has been theorized that in patients who have received intensive therapy or been given the drug for prolonged periods, a rebound kaliuresis could occur upon abrupt withdrawal. In such patients, withdrawal of triamterene should be gradual.
OBJECTIVE: The brain network serves as the physiological foundation for information processing of the brain. Many studies have reported abnormalities of gamma oscillations in Schizophrenia. The aim of this study was to investigate the gamma-band connectivity in Schizophrenia patients.
METHODS: We recorded the resting state electroencephalogram (EEG) for 15 schizophrenia patients with refractory auditory hallucinations and 14 healthy controls, with eyes open and closed. The brain network was constructed based on weighted phase lag index for gamma band. Whole scalp metrics (clustering coefficient, global efficiency and local efficiency) and local region metrics (degree and betweenness centrality) in the frontal and temporal lobes were computed. Correlation analyses between network metrics and symptom scales were examined to find associations with symptom severity.
RESULTS: Schizophrenia patients had larger global efficiency and local efficiency (p < 0.05) with eyes closed, probably representing greater brain activity and information exchange. For degree and betweenness centrality, schizophrenia patients showed an increase (p < 0.05) in the temporal lobe but a decrease (p < 0.05) in the frontal lobe with eyes closed and open, potentially account for the patients' symptoms such as hallucinations and thought disorders. Local efficiency and frontal lobe degree were positively and negatively correlated with the scales, respectively (both p < 0.05).
CONCLUSIONS: Altered connectivity of the resting state brain network has been revealed and may be associated with the core symptoms of schizophrenia. Our study provides promising evidence for the investigation of the pathological basis of Schizophrenia and could aid in objective diagnosis.
The invention provides a Rapamycin intraocular implantable drug releasing system taking bletilla striata gum as the carrier, which includes the medicine Rapamycin served as medicine and the carrier. The Rapamycin intraocular implantable drug releasing system is characterized in that the carrier is bletilla striata gum, the main component of the bletilla striata gum is glucomannan which is polymerized by mannose and glucose at the ratio of 1 to 4; the average molecular weight is from 65000 to 150000, the bletilla striata gum is accounted as glucomannan with a content being more than 85 percent, and the amount of the added medicine is accounted as the dry weight of the bletilla striata gum, being 0.05-50 percent. Cross-linking agent is also added in the bletilla striata gum. The cross-linking agent is formaldehyde, glutaraldehyde, glycol diglycidyl ether, and propanediol diglycidyl ether. Albumin, gelatin, etc. are also added in the bletilla striata gum. The bletilla striata gum can inhibit neovascularization and can resist tumor, the joint usage can take the effect of synergetic treatment. The system of the invention takes the full advantages that the bletilla striata gum are biodegraded inside the body; active medicine is slowly released; the dosage, the taking times, and the harmful side effect of the medicine are reduced; better curative effect can also be realized on the site at which the medicine is difficult to be absorbed.
BACKGROUND: Myocardial infarction (MI) is an acute condition in which the heart muscle dies due to the lack of blood supply. Previous research has suggested that autophagy and angiogenesis play vital roles in the prevention of heart failure after MI, and miR-106a is considered to be an important regulatory factor in MI. But the specific mechanism remains unknown. In this study, using cultured venous endothelial cells and a rat model of MI, we aimed to identify the potential target genes of miR-106a and discover the mechanisms of inhibiting autophagy and angiogenesis.
METHODS: We first explored the biological functions of miR-106a on autophagy and angiogenesis on endothelial cells. Then we identified ATG7, which was the downstream target gene of miR-106a. The expression of miR-106a and ATG7 was investigated in the rat model of MI.
RESULTS: We found that miR-106a inhibits the proliferation, cell cycle, autophagy and angiogenesis, but promoted the apoptosis of vein endothelial cells. Moreover, ATG7 was identified as the target of miR-106a, and ATG7 rescued the inhibition of autophagy and angiogenesis by miR-106a. The expression of miR-106a in the rat model of MI was decreased but the expression of ATG7 was increased in the infarction areas.
CONCLUSION: Our results indicate that miR-106a may inhibit autophagy and angiogenesis by targeting ATG7. This mechanism may be a potential therapeutic treatment for MI.
The majority of women entering substance use treatment have a trauma history, placing them at risk for revictimization and substance use relapse. The purpose of this project is to implement a pilot study to investigate the feasibility and preliminary efficacy of a peer support specialist-delivered violence prevention program for women in substance use treatment. The program entails a posttraumatic stress disorder (PTSD) screening, trauma-focused resource referral, and two session interpersonal violence prevention protocol for 60 participants. In this single arm trial, women are recruited from three substance use treatment facilities. Participants complete baseline, post-intervention, one-month, and three-month follow-up assessments. Self-report surveys assess demographics, trauma and sexual assault experiences, knowledge and attitudes towards sexual and intimate partner violence, protective behavioral strategies, and intervention satisfaction and engagement.
The present invention is in the fields of medicine, public health, immunology, molecular biology and virology. The invention provides compositions comprising a virus-like particle (VLP) or a virus particle and at least one antigen, particularly at least one feline antigen, and more particularly at least one feline antigen that is a human allergen. In certain embodiments, the antigen is a Fel d1 antigen or a fragment thereof, covalently linked to the VLP. The invention also provides methods for producing the compositions. The compositions of the invention induce efficient immune responses, in particular antibody responses, in mammals, particularly humans. The compositions and methods of the invention are useful in the production of vaccines, in particular for the treatment and/or prevention of allergies to cat dander and other cat antigens and allergens.
Oxygen is compulsory for mitochondrial function and energy supply, but it has numerous more nuanced roles. The different roles of oxygen in peripheral nerve regeneration range from energy supply, inflammation, phagocytosis, and oxidative cell destruction in the context of reperfusion injury to crucial redox signaling cascades that are necessary for effective axonal outgrowth. A fine balance between reactive oxygen species production and antioxidant activity draws the line between physiological and pathological nerve regeneration. There is compelling evidence that redox signaling mediated by the Nox family of nicotinamide adenine dinucleotide phosphate (NADPH) oxidases plays an important role in peripheral nerve regeneration. Further research is needed to better characterize the role of Nox in physiological and pathological circumstances, but the available data suggest that the modulation of Nox activity fosters great therapeutic potential. One of the promising approaches to enhance nerve regeneration by modulating the redox environment is hyperbaric oxygen therapy. In this review, we highlight the influence of various oxygenation states, i.e., hypoxia, physoxia, and hyperoxia, on peripheral nerve repair and regeneration. We summarize the currently available data and knowledge on the effectiveness of using hyperbaric oxygen therapy to treat nerve injuries and discuss future directions.
PURPOSE:To obtain the title composite powder without damaging the function of the object powder such as org., inorg., and metal powder, without reacting with the coexistent components in various systems, and providing a stable product by the mixing with all sorts of bases by uniformly dispersing metal powder in water-swollen clay mineral powder. CONSTITUTION:The aq. dispersion of one or >=2 kinds among org., inorg., or metal powder and a water-swollen clay mineral is spray-dried to obtain composite powder wherein one or >=2 kinds among, org., inorg., or metal powder are contained in the powder consisting of the water-swollen clay mineral. The water-swollen clay mineral is phyllosilicate belonging to a smectite group, and montmorillonite, beidellite, etc., can be exemplified. The powder of polyamide resin, polyester resin, etc., can be exemplified as the org. powder, titanium dioxide, talc, calcium carbonate, etc., can be exemplified as the inorg. powder, and the powder of aluminum, gold, silver, iron, copper, etc., can be exemplified as the metal powder.
504,618. Serums &c. BASKIN. M. J. Oct. 25, 1937. No. 29063. [Class 81 (i)] A material for use in determining the presence of semen is obtained by heating material containing mammalian spermatozoa in water or a salt solution to render the spermatozoa non- specific. The salt solution is preferably isotonic and the temperature of heating 50-100‹ C. In the use of the material as a determinant it is injected into an animal the blood of which is introduced into a solution containing the matter to be tested. The production of a precipitate indicates the presence of semen.
Sepsis remains a significant cause of mortality and morbidity worldwide, with limited effective treatment options. The T-cell immunoglobulin and mucin domain-containing molecule 3 (TIM-3) has emerged as a potential therapeutic target in various immune-related disorders. This narrative review aims to explore the role of TIM-3 in sepsis and evaluate its potential as a promising target for immunotherapy. We discuss the dynamic expression patterns of TIM-3 during sepsis and its involvement in regulating immune responses. Furthermore, we examine the preclinical studies investigating the regulation of TIM-3 signaling pathways in septic models, highlighting the potential therapeutic benefits and challenges associated with targeting TIM-3. Overall, this review emphasizes the importance of TIM-3 in sepsis pathogenesis and underscores the promising prospects of TIM-3-based immunotherapy as a potential strategy to combat this life-threatening condition.
This is an open-label phase I, dose-escalation safety study in subjects with refractory solid tumors. The primary objectives of the study are to assess the safety, tolerability, and pharmacokinetics of PG-11047. PG-11047 will be administered as a 60-minute intravenous infusion on days 1, 8 and 15 of each 28 day cycle. The planned minimum treatment schedule is 2 cycles (8 weeks) of PG-11047 treatment. Subjects who tolerate treatment may be eligible to receive additional cycles as per investigator's medical judgment. Evaluation of anti-tumor response will be performed every 2 cycles.
The invention relates to a preparation method of a liquid precursor lipidosome. The preparation method comprises the following steps: dissolving a drug, a lipid material and hydroxypropyl starch in propanediol together, and adding an aqueous solution to form a drug-supported lipidosome before use; or dissolving the drug and the lipid material in propanediol together, and adding an aqueous solution containing hydroxypropyl starch to form the drug-supported lipidosome before use. In the preparation process, the particle size of the drug-supported lipidosome is adjusted and controlled to a micron or nanometer range by changing the concentration of the lipid material in propanediol or changing the amount ratio of propanediol to the aqueous solution. The preparation method is simple, drug envelopment rate is high and drug particle size is controllable, thereby facilitating the penetration of skin into skin, mucosa or in-vivo biomembrane barriers to exert the long-acting action of the drug, and the method has a wide applicable drug range and is especially suitable for the drugs with poor amphipathicity or large molecular weight. The invention also relates to an application method of the liquid precursor lipidosome. The liquid precursor lipidosome can be applied to spray, jellies, injection and other dosage forms, and can meet the local or whole body treatment requirements of mucosa, skin, wound surfaces and cavity channels.